Азимед

Quick links to important sections

Азимед

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Азимед

Quick Facts

Property Description
Active ingredient Azithromycin dihydrate
Forms Tablets, Capsules, Oral Suspension, IV Solution
Pharmacological class Antibiotic (Azalide/Macrolide)
Common use Systemic treatment of bacterial infections
Origin Semi-synthetic (Erythromycin derivative)

Азимед: Definition, Active Ingredient, and Pharmacological Class

Азимед is a systemic prescription medication whose sole active component is Azithromycin dihydrate. It is classified as an antibiotic and belongs specifically to the Azalide subclass of macrolide antimicrobials. This chemical classification means the drug is fundamentally designed to combat infections caused by susceptible bacteria throughout the body.

Azithromycin is a semi-synthetic substance, structurally derived from the older macrolide, Erythromycin, but chemically modified to enhance its stability and pharmacological profile. Pharmacological studies have confirmed its unique advantage of achieving high concentrations in tissues and maintaining a prolonged terminal half-life compared to other antibiotics in its class. This characteristic underscores the drug's specialized ability to sustain its antibacterial effect over a longer period, making it clinically recognized for scenarios requiring less frequent dosing.

What Type of Preparation and General Purpose Does Азимед Serve?

The brand Азимед (Azimed) is a single-ingredient product manufactured in several high-level dosage forms, including film-coated tablets, capsules, powder for preparing an oral suspension (often formulated for ease of administration in pediatric patients), and a solution for intravenous injection, allowing for both oral and systemic administration.

The general purpose of Азимед is to resolve active bacterial illnesses by inhibiting the microorganisms' growth. The compound achieves this by acting as an effective broad-spectrum antibacterial agent that selectively interferes with the bacteria's process of protein synthesis, a mechanism central to its efficacy. This ensures that the medication directly targets and impairs the structural integrity and reproductive ability of the bacterial pathogens, supporting the immune system in clearing the infection.

What side effects are possible with Азимед?

Possible Side Effects and Safety Information

The safety profile of Азимед (Azithromycin) is classified in official regulatory documents based on the frequency and the System-Organ-Class (SOC) of the documented adverse reactions. Information in this section is derived strictly from government regulatory sources and official product labeling.

Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions, generally classified as Very Common or Common in regulatory labeling, often involve the gastrointestinal system and include:

  • Diarrhea
  • Abdominal pain
  • Nausea and Vomiting
  • Headache
  • Dizziness and Pruritus (itching)

Serious Adverse Reactions and Systemic Constraints

Official labeling highlights several serious adverse reactions and safety constraints, which are generally categorized as uncommon or rare in frequency. The regulatory profile emphasizes risks to specific body systems:

  • Cardiac Disorders: Azithromycin is associated with the risk of QT interval prolongation and subsequent development of a potentially fatal irregular heart rhythm, known as Torsades de Pointes.
  • Hepatobiliary Disorders: Reports include severe hepatotoxicity, such as hepatic necrosis and hepatic failure, which can be fatal. Caution is specifically noted for individuals with existing severe hepatic impairment.
  • Hypersensitivity: Rare but serious cutaneous reactions, including Stevens-Johnson Syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported.
  • Gastrointestinal Risk: As with many antibiotics, the possibility of Clostridioides difficile-associated diarrhea (CDAD) is documented.
  • Myasthenia Gravis: Official labeling notes the potential for exacerbation of muscle weakness in individuals with this condition.

Population-Specific Safety Considerations

Specific constraints are defined for certain patient groups. Older adults may have increased susceptibility to the cardiac arrhythmia risk. Additionally, the label documents the reporting of Infantile Hypertrophic Pyloric Stenosis (IHPS) following use in neonates (up to 42 days of life).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents regarding Азимед (Azithromycin) overdose establish a profile centered on acute gastrointestinal distress and a potential for severe cardiac toxicity. This information is derived strictly from government regulatory documentation.

Documented Manifestations

Overexposure to Azithromycin is primarily characterized by amplified gastrointestinal symptoms, including severe nausea, vomiting, diarrhea, and abdominal pain. These manifestations are generally consistent with the adverse reactions seen at normal therapeutic doses. The documentation also notes that the macrolide class may be associated with reversible hearing loss.

Severe Outcomes and Emergency Action

The most significant regulatory concern in overdose is the potential for serious cardiovascular disruption. Azithromycin can cause a prolongation of the QT interval, which may lead to Torsades de Pointes, a rare but life-threatening irregular heart rhythm. This cardiac risk is noted to be heightened in specific patient groups, including the elderly and women.

Immediate medical attention is required for any symptom indicative of severe toxicity or cardiac distress. This includes, but is not limited to, experiencing an irregular heartbeat, dizziness, shortness of breath, or fainting. Individuals must call emergency services immediately if the affected person has collapsed, had a seizure, or cannot be awakened.

Management Protocol

Regulatory statements confirm that no specific antidote is available for Azithromycin overdose. Management involves implementing general symptomatic and supportive measures as required, and the administration of medicinal charcoal is indicated to aid treatment.

Therapeutic Uses of Азимед

What Азимед Treats: Main Uses and Benefits


The primary purpose of Азимед (Azithromycin) is to provide systemic support for managing bacterial infections across several key therapeutic domains. The medication is commonly used to help patients cope more steadily during episodes of heightened symptoms. It is prescribed for specific infections of the ears, lungs, sinuses, skin, throat, and reproductive organs. This approach contributes to easing the overall symptom load and improved comfort.

Therapeutic Focus and Symptom Relief

Азимед is applied in clinical settings that involve acute or disruptive symptom patterns, and is particularly relevant for easing symptoms in acute bacterial exacerbations of bronchitis, pneumonia, sinusitis, and pharyngitis. It supports the management of conditions presenting with localized discomfort, such as uncomplicated skin and soft tissue infections (e.g., cellulitis and impetigo), and is relevant for easing symptoms related to certain Sexually Transmitted Infections (STIs), like those caused by Chlamydia trachomatis. The treatment is commonly used when symptoms cluster into patterns requiring supportive management, and supports the process of symptomatic management.

“The general application of Azithromycin is aligned with domains where short-term symptom management is appropriate, assisting with maintaining functional stability.”


Quick Fact Block

Property Description
Quick Fact: Relief for Systemic Discomfort
Symptom Goal Easing fever, pain, and congestion during acute bacterial episodes.
Use Scenario Commonly used for community-acquired respiratory infections.

This section exclusively describes symptomatic relief and therapeutic scope, without mentioning mechanisms, doses, safety, or instructions for use.

Regulatory References

  1. NIH MedlinePlus overview of Azithromycin

Eligibility and Restrictions for Use

The eligibility profile for Азимед (Azithromycin) is strictly defined by regulatory authorities based on patient population, age, and existing health conditions.

Absolute Contraindications (Must Not Use)

The medicine is formally contraindicated in individuals with a known allergy or severe hypersensitivity reaction to Azithromycin, Erythromycin, or any macrolide or ketolide antibiotic. Use is also prohibited for patients with a documented history of cholestatic jaundice or liver dysfunction directly related to previous Azithromycin administration.

Restrictions and Conditional Use

Use is generally established for adults and for pediatric patients 6 months of age and older for certain infections, although efficacy is not established for specific indications in children under two years old. Caution is necessary when prescribing to neonates (up to 42 days old) due to reports of Infantile Hypertrophic Pyloric Stenosis (IHPS). The medicine must be used with caution in patients with severe renal impairment and is not recommended for those with severe hepatic disease. Use also requires caution in patients with underlying cardiac conditions that may prolong the QT interval. Oral formulations are not recommended for severe illnesses, such as pneumonia, requiring hospitalization.

Pregnancy and Lactation Status

Use during pregnancy is restricted and considered only if clearly needed, as adequate, controlled studies are limited. The drug is present in breast milk, requiring a decision to either discontinue nursing or discontinue the medication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define specific interaction patterns for Azithromycin (Азимед). Co-administration with certain medicinal products is formally contraindicated in official labeling, including Pimozide and Ergot Alkaloids (like Ergotamine or Dihydroergotamine), due to the risk of severe cardiac or circulatory events.

Pharmacokinetic and Pharmacodynamic Interactions

Azithromycin does not significantly inhibit or induce the Cytochrome P450 enzyme system, setting its interaction profile apart from some other macrolides. However, pharmacokinetic changes occur with other substances. For example, co-administration with Nelfinavir is officially documented to increase the systemic exposure of Azithromycin itself. Conversely, concurrent use of Antacids containing Aluminum or Magnesium is known to reduce the peak plasma concentration ( Cmax) of Azithromycin. This effect requires a mandatory time separation rule of at least two hours between the administration of the two products.

Pharmacodynamic interactions include an additive risk of QT interval prolongation when taken with other QT-prolonging agents, and the potential to potentiate the effects of oral anticoagulants such as Warfarin, which necessitates close monitoring of Prothrombin Time/INR.

Mechanism of Action

The action of Azimed is defined by two primary mechanistic domains: the direct inhibition of bacterial replication and the modulation of host inflammatory signaling, both mechanisms contributing to the physiological consequence of microbial load reduction.


Core Mechanism: Inhibition of Bacterial Protein Synthesis

This domain focuses on the drug's molecular interaction with the bacterial 70S ribosome. Azithromycin binds specifically to the 50S ribosomal subunit's exit tunnel, acting as a physical blocker to inhibit the elongation step of the protein synthesis pathway. This action results in the bacterium's inability to synthesize functional proteins required for growth and division, leading directly to a bacteriostatic physiological effect that arrests microbial proliferation.


️ Secondary Mechanism: Modulating Host Inflammatory Signaling

This mechanism involves the drug's ability to accumulate in host immune cells and engage certain pro-inflammatory pathways. By engaging cascades that influence transcription factors like NF-kappaB, Azithromycin contributes to the attenuation of specific cytokine production at the site of infection. This modulation results in suppressed inflammatory signaling, which attenuates pathways associated with increased tissue pathology caused by immune activity.


⏳ Mechanism Constraints and Sustained Action

The drug's mechanism is constrained in strains where bacteria have evolved defenses like efflux pumps or target site modification (23S rRNA methylation), which prevent the drug from achieving its required inhibitory concentration. Conversely, its physiological action is sustained due to its tissue affinity, allowing the molecule to sustain the required inhibitory concentration for prolonged action against the target.

Dosage and Administration Information

Official Administration Guidelines

Азимед (Azithromycin) is administered via the oral route (tablets, capsules, or suspension) or as an intravenous (IV) infusion. The specific official dosing regimen is critical and varies based on the condition being treated and the patient's age and weight, typically requiring a once-daily administration.

Dosing and Timing Rules

  • Oral Dosing: Common adult regimens include a total dose of 1500 mg over 3 or 5 days, such as 500 mg on Day 1 followed by 250 mg once daily on Days 2 through 5. For certain infections, a single 1 gram dose is prescribed.
  • Pediatric Dosing: Dosing for children (generally 6 months of age and older) is calculated based on body weight, such as 10 mg/kg once daily for 3 days for certain infections.
  • Meal Relation: Azithromycin tablets and standard oral suspension can be taken with or without food. However, capsules should be taken either one hour before or two hours after a meal.

Preparation and Administration Steps

  • Oral Suspension: The bottle must be shaken well before each dose, and the prescribed amount must be accurately measured using a proper dosing device.
  • IV Infusion: The powder for injection must be reconstituted and subsequently diluted in an appropriate solution to a final concentration of 1 mg/mL or 2 mg/mL. The resulting solution must be administered as an IV infusion over a minimum duration of 60 minutes. IV administration must not be performed as a bolus or intramuscular injection.
  • Missed Dose: If a dose is missed, it should be taken as soon as remembered. If it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Double doses are prohibited.

These guidelines define the required procedural sequence for administering the medication, covering the route, frequency, and preparation steps to ensure the medicine is used correctly.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Азимед

Research for this medicine primarily involves studies that monitor and measure outcomes related to physical discomfort and systemic changes during periods when symptoms are active.


Evidence for Use in Acute Respiratory and Systemic Infections

Research examined the use of Azithromycin in conditions characterized by acute or disruptive episodes, such as serious lung infections and infections that may cause systemic discomfort.

Studies for Acute Respiratory Infections (Pneumonia and Bronchitis)

Randomized Controlled Trials (RCTs) and large observational cohort studies were primarily used in research examining Community-Acquired Pneumonia (CAP) and Acute Bacterial Exacerbations of Chronic Bronchitis (AECB). The studies explored short-term changes in symptoms and focused on outcomes reflecting daily functioning or activity level.

For CAP, research monitored physiological strain or stress by measuring endpoints such as the time it took for a patient to reach clinical stability (e.g., fever resolution) and the rate of hospitalization or mortality. Some studies reported different measurements of clinical failure in trials for CAP when compared to the measurements observed for certain other study drugs. However, some of these early trials were open-label, meaning the interpretation of the findings must account for the lack of blinding, which can impact measurements. In AECB, studies monitored short-term symptom changes and clinical outcomes over the initial course of the illness. Studies observed different patterns in the measurements of clinical outcomes, with findings being mixed across studies that monitored clinical success.

Research on Skin and Soft Tissue Infections and STIs

Azithromycin was studied for its application in uncomplicated Skin and Soft Tissue Infections (SSTI) and certain Sexually Transmitted Infections (STIs). These studies primarily focused on outcomes related to microbiological eradication and patient-reported outcomes describing perceived discomfort. For STIs, research typically involved comparative RCTs of the medicine’s single-dose regimen. Studies report how symptoms evolved in the observed populations, and findings reflect the measured rates of microbiological cure when evaluated alongside other study drugs in the populations studied.


Long-Term and Maintenance Study Evidence

Azithromycin was evaluated in long-term research scenarios, often involving follow-up durations of six months to over a year, specifically for the prevention of episodes of heightened symptom activity in patients with chronic lung conditions. Research describes that the measured frequency of these exacerbations over the long-term observation period differed from the frequency measured in the control groups.


Understanding Research Limitations and Gaps

The research base for Azithromycin provides context but not individual predictions, and certain limitations are noted in the scientific literature. Evidence quality varies across studies, with some older trials being open-label. A key limitation is that results apply only to the populations studied, and there is limited information for long-term outcomes beyond the one-year mark. Furthermore, the increasing bacterial resistance to macrolides in many regions means that the reported findings from older efficacy trials may not fully reflect current expected outcomes in areas with high resistance rates, a factor that is continually monitored by public health and regulatory agencies.

Frequently Asked Questions (FAQ)

Common questions about Азимед (FAQ)


Q: How quickly should someone expect to feel better after starting Азимед?

A: Studies used for regulatory approval often measure the time it takes for patients to reach clinical stability, such as when a fever resolves. Official information indicates that the medicine is designed to sustain its effect. However, the exact time when an individual may perceive improvement in symptoms can vary depending on the type and severity of the infection.


Q: Is Азимед known to cause stomach upset?

A: Yes, official product information lists gastrointestinal disturbances among the most common side effects. These reactions commonly include symptoms such as diarrhea, nausea, vomiting, and abdominal pain.


Q: What are the most commonly reported skin reactions from Азимед?

A: Regulatory documents list pruritus (itching) as a common side effect. It is important to note that very rare, serious skin reactions, such as Stevens-Johnson Syndrome (SJS), have also been reported and require immediate medical attention.


Q: What happens if a person uses alcohol while taking Азимед?

A: Official drug labels for Azithromycin do not typically warn of a formal, direct drug-alcohol interaction. Alcohol consumption may potentially exacerbate common gastrointestinal side effects. It is generally recognized that alcohol may also impact the body's ability to recover from an infection.


Q: Can Азимед affect birth control pills?

A: Official drug interaction studies generally do not show that Azithromycin affects the effectiveness of hormonal oral contraceptives. However, official patient information advises that severe gastrointestinal issues, such as vomiting or severe diarrhea, may potentially impact the absorption of oral contraceptives.


Q: Is Азимед generally considered appropriate for older adults?

A: The medicine is generally used across adult age groups. However, regulatory information specifically notes that older individuals may have an increased susceptibility to the risk of abnormal heart rhythms (QT prolongation), which requires precaution.


Q: Can Азимед make people dizzy or affect their ability to drive?

A: Dizziness and headache are commonly reported side effects. Because these effects may occur, official guidance indicates that patients should consider their personal reaction to the medicine before engaging in activities like operating machinery or driving.


Q: How does Azithromycin affect the 'good' bacteria in the gut?

A: As an antibiotic, Azithromycin works by disrupting susceptible bacteria. This action naturally alters the normal bacterial balance (flora) in the colon. This alteration is related to the possibility of diarrhea caused by an overgrowth of Clostridioides difficile bacteria, which is noted in official warnings.


Q: Do official sources mention Азимед having an effect on kidney function?

A: Official documents state that no dosage adjustment is typically required for people with mild to moderate kidney impairment. However, caution is generally advised when prescribing the medicine to those with severe kidney impairment.


Q: Is it possible for a cold or flu to be treated with Азимед?

A: Regulatory documents state that Azithromycin is an antibiotic used to treat infections caused by susceptible bacteria. It is explicitly noted that this medicine is not effective against illnesses caused by viruses, such as the common cold or influenza (the flu).


Q: Do studies suggest Азимед is effective for common ear infections?

A: Yes, the medicine is officially indicated and approved for treating specific types of bacterial ear infections (acute otitis media) in children who are six months of age and older, according to regulatory documents.


Q: How long does Азимед typically stay in the body after the last dose?

A: Pharmacokinetic studies show that the medicine has a long elimination half-life, which can be between 2 and 4 days. Due to this characteristic and its distribution into body tissues, detectable amounts of the medicine may remain in the system for approximately 15 days after the final dose.


Q: Is it common to feel unusually tired while on Азимед?

A: Unusual tiredness or weakness is not generally listed among the most common side effects in regulatory documents. However, it is noted as a potential symptom of rare, more serious adverse events, such as liver or cardiac problems, and are factors that a healthcare provider would monitor.


Q: What is the risk of developing a serious allergic reaction to Азимед?

A: Serious allergic reactions, including severe swelling (angioedema) and anaphylaxis, are reported as rare events in the official warnings. Regulatory information notes that these severe reactions can sometimes recur even after initial treatment and may necessitate extended medical observation or treatment.


Q: Can Азимед interact with common supplements like multivitamins?

A: Official documents specifically warn that the medicine's concentration in the blood may be reduced when taken with antacids containing Aluminum or Magnesium. Because some multivitamins contain these minerals, official documents advise a time separation of at least two hours between the administration of Azithromycin and these products.


Q: How do doctors generally determine if Азимед is the right choice for an infection?

A: The decision is based on whether the infection is caused by bacteria that are confirmed, or strongly suspected, to be susceptible to Azithromycin. Regulatory guidelines emphasize that antibiotics should only be prescribed when a bacterial cause is established, and not for viral infections.


Q: Does Азимед carry a risk for tendon problems?

A: No, Azithromycin is an azalide antibiotic and is not formally associated with the risk of tendonitis or tendon rupture. Regulatory warnings for this medicine focus on risks to the cardiovascular and hepatobiliary (liver) systems, unlike warnings for the fluoroquinolone class of antibiotics.


Q: What is the proper way to discontinue Азимед if a person experiences side effects?

A: Regulatory guidance indicates that patients should immediately stop taking the medicine and seek emergency medical attention if they experience signs of a serious side effect, such as severe rash or breathing difficulties. For common, mild side effects, the need to stop the medication should be discussed with a healthcare provider.


Q: What is the relationship between Азимед and macrolide antibiotics?

A: Azithromycin is classified as an Azalide, which is a distinct subclass of the Macrolide group of antibiotics. It is chemically related to Erythromycin (a macrolide) but has a unique structure that gives it a different range of action and a longer duration in the body.


Q: Is a metallic taste in the mouth a known side effect of Азимед?

A: Yes, official labeling includes changes in taste (dysgeusia), which can be perceived as a metallic taste, as a documented side effect. This is generally considered a less common adverse reaction.


Q: Why do official documents warn about a potential for hearing changes with Азимед?

A: Regulatory documents report that macrolide antibiotics, including Azithromycin, have been associated with a potential for hearing impairment or loss. It is important to know that this effect is generally reported as reversible once the medicine is stopped.


Q: Is it true that Азимед can be used to treat certain sexually transmitted infections?

A: Yes, Azithromycin is officially indicated and approved for the treatment of certain sexually transmitted infections (STIs), such as urethritis and cervicitis, when they are caused by susceptible organisms.


Q: How is the long-term safety of Азимед described in regulatory documents?

A: The medicine is primarily prescribed for short-term courses to treat active bacterial infections. While studies have explored its use over longer periods for preventing flare-ups in chronic lung disease, official safety communications have been issued to warn against long-term use in certain patient groups due to specific, rare risks.


Q: How does the time of day a person takes Азимед influence its effect?

A: Official guidance for the tablets and standard suspension indicates that they can generally be taken with or without food. This suggests the specific time of day is not critical to the medicine's overall systemic effect, as long as the prescribed dosing rules are followed.


Q: Can a person be allergic to Азимед but not penicillin?

A: Yes. A person can have a specific allergy to Azithromycin (an azalide) without having an allergy to penicillin. The contraindication is specifically for those with a known severe reaction to Azithromycin or any other macrolide or ketolide antibiotic.


Q: What general expectations should someone have about the duration of side effects from Азимед?

A: Common side effects like gastrointestinal upset are often transient, meaning they may lessen or resolve as the body adjusts to the medication. However, any signs of serious adverse reactions, such as those affecting the heart or liver, may persist or worsen and warrant immediate consultation with a healthcare provider.


Q: Is Азимед classified as a 'critical' antibiotic by health organizations?

A: The World Health Organization (WHO) has classified Azithromycin in its Watch category within the AWaRe framework. This indicates that it is an important, high-priority antibiotic that should be used judiciously to help monitor and prevent antimicrobial resistance.


Q: Does taking Азимед make someone more sensitive to the sun?

A: Regulatory-affiliated patient information for Azithromycin does indicate a potential for increased sensitivity to the sun, a condition called photosensitivity. Because of this, official information frequently includes advice to use protective measures, such as clothing and sunscreen, when exposed to the sun.

How should Азимед be stored and disposed of?

Storage and Disposal of Azithromycin

The storage and disposal of Azithromycin (Азимед) must strictly adhere to the conditions documented in official regulatory labeling.

Storage Component Required Condition (Regulatory Basis)
Tablets and Unmixed Powder Store at controlled room temperature (20 C to 25 C).
Reconstituted Suspension Store at or below 30 C (86 F); Do not freeze.
Protection and Container Must be kept in the original container, tightly closed, protected from moisture and excess heat.
Stability Limit The liquid suspension has a limited stability period (e.g., 10 days) after reconstitution and must be discarded after that time.
Child Safety Keep the medicine out of the reach and sight of children.
Disposal Rule Unused medicine must not be disposed of via wastewater or household trash; dispose of according to local regulatory requirements or drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Азимед found in:

A-Z Index: